ImmunoGen, Inc.

Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. We are a clinical-stage biotechnology company that develops targeted cancer therapeutics using antibody-drug conjugate (ADC) technology. Our lead product candidate, mirvetuximab soravtansine, is in Phase 3 study for FRα-high, platinum-resistant ovarian cancer, and Phase 1b/2 testing in combination regimens. Our novel IGN candidate for hematologic malignancies, IMGN632, is in Phase 1 studies. We also have two other early stage assets in development: IMGC936, an ADAM9-targeting ADC, and IMGN151, our next generation anti-folate receptor alpha ADC. Learn more about who we are, what we do, and how we do it at www.immunogen.com.